Moderna Generated $1.94 Billion in Revenue During the First Quarter, with $1.73 Billion Coming from Its COVID-19 Shot

Company Now Has the Rights to Distribute & Sell Three of the Most Popular COVID-19 Vaccines in the World: The Pfizer-BioNTech; Moderna and J&J COVID-19 Vaccines

San Clemente, CA - (NewMediaWire) - June 29, 2021 - Global WholeHealth Partners Corp. (OTC: GWHP), a company that offers one of the largest lines of COVID 19 tests including SARS-CoV-2 viruses and that states that its Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses, and that recently announced that they had acquired the rights to be able to distribute and sell both Pfizer-BioTech and Johnson & Johnson’s COVID-19 vaccine, today announced that they have now, also, acquired the rights to sell and distribute Moderna’s vaccine.

As with the Johnson & Johnson 8K filed on June 10, 2021, for the J&J rights, the Company filed on June 16, 2021, for Pfizer and filed for Moderna on June 25, 2021, stating that “Effective June 22, 2021, Global WholeHealth Partners Corporation (the “Company”) was granted the rights from Nunzia Pharmaceutical Inc. (“Nunzia”) to distribute and sell the Moderna COVID-19 Vaccine. The Company will serve as a broker for Nunzia and follow the same sales order processing as used by Nunzia in connection with the distribution and sale of the Vaccine.”[1]

According to reports: “With additional supply agreements under its belt, Moderna now predicts its vaccine will generate $19.2 billion by year’s end. In comparison, rival drugmaker Pfizer posted  $3.5 billion in COVID-19 vaccine sales during its first quarter and also upped its anticipated 2021 revenues to a whopping $26 billion, according to its earnings report released on Tuesday. More supply deals are likely on the horizon for Moderna, executives hinted. In Europe, mRNA vaccines from Moderna and Pfizer have already started taking a larger slice of the COVID-19 vaccine market…[2]

The Company already offers one of the largest lines of COVID 19 tests, including the strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein.

Mr. Charles Strongo, the CEO and Chairman of WholeHealth Products Inc., said: “Global will now have both J&J’s extremely convenient 1-shot vaccine, we now have the rights to the Pfizer-BioNTech and Moderna vaccines, which are generally considered the ones with highest efficacy…. Including against variants. ”

About Global WholeHealth Partners Corp

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians' offices, and medical clinics in the US and abroad. The Company has the capacity to deliver hundreds of thousands of tests, and can ramp up to 1 million tests per day and the Company presently has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA, many of which are approved for OTC use, and 15 POC products approved by the CLIA WAIVED FDA.

For more information please go to: www.gwhpcorp.com

Media: Charles Strongo 714-392-9752

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

https://c212.net/c/img/favicon.png?sn=LA68315&sd=2021-05-06View original content to download multimedia:http://www.prnewswire.com/news-releases/alzheimers-disease-is-the-leading-cause-of-dementia-alzheimers-diagnostics-attained-by-global-wholehealth-partners-corp-otc-gwhp-as-a-leading-researcher-301285232.html

SOURCE Global WholeHealth Partners Corp

[1]  https://www.otcmarkets.com/filing/html?id=15053509&guid=JyUkkaKc61nC_yh

[2]https://www.fiercepharma.com/pharma/moderna-posts-massive-year-over-year-growth-thanks-to-1-7b-covid-19-vaccine-sales